Leadership Will McGuire - President and CEO Mr. McGuire joined Second Sight in August 2015 as President and CEO. Most recently he was with Volcano Corporation, where he was President of Americas Commercial since 2014 and prior to that, Senior Vice President and General Manager of Coronary Imaging, Systems and Program Management since 2013. Prior to that Mr. McGuire served as Vice President and General Manager of Patient Monitoring at Covidien. He previously served as President and Chief Executive Officer of AtheroMed, Inc., a venture capital-backed peripheral atherectomy company, prior to which he was Chief Operating Officer at Spectranetics Corporation, a publicly-traded medical device company. In addition, Mr. McGuire held various positions at Guidant Corporation from 1998 to 2005 including General Manager of Guidant Latin America; Director of U.S. Marketing for Vascular Intervention (VI); Director of Global Marketing for VI; and, Production Manager for Coronary Stents. Prior to 1998, Mr. McGuire held positions in Finance and Production at IVAC Medical Systems. A graduate of the Georgia Institute of Technology, Mr. McGuire received his M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. Robert Greenberg, MD, PhD – Chairman Dr. Greenberg was appointed Chairman of the Board in August 2015. He is a founder of the company and served as President, Chief Executive Officer and Director from 1998 until August 2015. From 1991 to 1997, Dr. Greenberg conducted pre-clinical and clinical trials demonstrating the feasibility of retinal electrical stimulation to elicit visual perceptions. From 1997 to 1998, he served as a lead reviewer for IDEs and 510(k)s at the Office of Device Evaluation at the U.S. Food and Drug Administration in the Neurological Devices Division. In 1998, he received his medical and doctorate degrees from The Johns Hopkins School of Medicine. Dr. Greenberg currently is also the Chairman of the Board of Directors of the Southern California Biomedical Council and the Alfred Mann Foundations. In addition he sits on the Board of Directors of a public company, Pulse Biosciences, using nanosecond pulses to modulate cellular activity applied to oncology, dermatology and other minimally invasive applications. Steve Okland – Commercial Vice President, U.S. and Canada Mr. Okland joined Second Sight in March 2016 as Commercial Vice President, U.S. and Canada. Most recently he was president of Sanford Rose Associates – Okland Group, Inc., which specialized in commercial executive talent acquisition for early stage to mid-cap medical device companies. Previously, he served as Vice President, Worldwide Marketing and Sales, at Miramar Labs, Inc., a medical device company targeting dermatologic medical conditions, where he led all commercialization activities. Prior to that, Mr. Okland served as Vice President, Worldwide Marketing and U.S. Sales at Medivance, Inc., and directed the turnaround of all commercialization activities resulting in a $250M acquisition by Bard Medical. At Spectranetics, Inc., as Vice President, U.S. Sales and Marketing, he directed all U.S. sales and marketing operations during a period when the company was named to Fortune’s 100 Fastest Growing Companies three years in a row. He also held several sales positions of increasing responsibility during 12 years at Boston Scientific Corporation and at Johnson & Johnson Medical, Inc., where he began his career. He earned a Bachelor of Science degree from the University of Wisconsin and a Masters of Business Administration from Texas Christian University. Gregoire Cosendai, PhD - Vice President of European Operations. Dr. Cosendai was our Director of European Operations from 2008 to 2010 and has since 2010 been our Vice President of European Operations. Between 2005 and 2008 he acted as a consultant for Second Sight. From 2001 to 2008 he was director of business development for the Alfred E. Mann Foundation. From 1995 to 2001 he was clinical engineer at the ENT clinic at the Geneva Hospital. Dr. Cosendai received a PhD from EPFL Lausanne on developing new speech coding strategies for cochlear implants and a Master of Electrical Engineering (Ing. dipl. EPFL elec.) from EPFL Lausanne. Thomas B. Miller – Chief Financial Officer Mr. Miller has been our Chief Financial Officer since May 2014. From 2000 to 2014 he was Chief Financial Officer of Ixia, a public company engaged in the design and manufacture of test and monitoring products for the telecommunications industry. From 1997 to 1999, Mr. Miller was the Director of Finance and Controller of CoCensys, a public biotechnology company engaged in the discovery and development of drugs to treat neurological and psychiatric disorders. He received a Masters of Business Administration from the University of Southern California and a Bachelor of Arts, Economics from the University of California, Berkeley. Edward Randolph – Vice President of Manufacturing Mr. Randolph has been our Vice President of Manufacturing since 2007. From 2003 to 2007, he was Director of Manufacturing Engineering at Boston Scientific Corp., a worldwide manufacturer of medical devices and products. From 2001 to 2003, Mr. Randolph was a Director of Manufacturing Engineering at Cygnus, Inc., manufacturer of non-invasive transdermal drug delivery systems. He received his Master of Science in Engineering from Stanford University and his Bachelor of Science in Architecture from Massachusetts Institute of Technology.